Defence Therapeutics Announces Convertible Debenture Interest Payment

Defence Therapeutics settles $160,000 interest with shares and receives $190,670.42 from Sorbie deal.

What the company is saying

Defence Therapeutics Inc. (CSE:DTC, OTCQB:DTCFF, FSE:DTC) is reporting two financial transactions: the issuance of 320,000 common shares to satisfy $160,000 in accrued and unpaid interest on $2,000,000 principal convertible debentures dated September 15, 2025, bearing 8% annual interest, and the receipt of a $190,670.42 settlement payment under its sharing agreement with Sorbie Bornholm LP. The company frames these as routine updates, referencing statutory compliance for the share issuance (four months plus one day hold) and directing investors to prior news releases for more details. The announcement highlights the ongoing nature of the Sorbie agreement, noting 606,060 placement shares released to SBLP, 9,090,911 placement shares still in escrow, and 15 settlement payments remaining. The tone is factual and procedural, with no forward-looking statements or promotional language. No executives are quoted or named, and no operational or strategic commentary is provided.

What the data suggests

The company has satisfied $160,000 in accrued interest on its $2,000,000 convertible debentures by issuing 320,000 common shares, implying a value of $0.50 per share for this transaction. The 8% annual interest rate on the debentures is in line with typical convertible debt terms for small-cap biotech firms. The statutory hold period for these shares is four months plus one day, limiting immediate liquidity for recipients. Under the Sorbie Bornholm LP sharing agreement, Defence received a third settlement payment of $190,670.42 on October 14, 2026, corresponding to 606,060 placement shares released to SBLP. As of this announcement, 9,090,911 placement shares remain in escrow, and 15 settlement payments are outstanding, indicating a multi-stage capital arrangement with ongoing dilution potential. The figures are precise and the disclosure is complete for these transactions, but there is no information on the company's broader financial health, cash position, or operational progress.

Analysis

The announcement is a factual update on two financial transactions: the issuance of shares to satisfy accrued interest on convertible debentures and the receipt of a settlement payment under a sharing agreement. All claims are realised and supported by specific figures and dates, with no forward-looking projections or promotional language. There is no attempt to frame these routine capital management actions as transformative or to suggest imminent operational or financial upside. The tone is strictly informational, and there are no exaggerated claims or narrative inflation. The data disclosed is complete for the scope of the announcement, and there is no gap between narrative and evidence.

Risk flags

• ●Ongoing dilution risk is present due to the issuance of 320,000 shares for interest and the release of 606,060 placement shares to Sorbie Bornholm LP, with 9,090,911 more shares still in escrow. This could pressure the share price if future settlements continue at this scale.
• ●The company's reliance on convertible debentures and structured share-based settlements suggests limited access to non-dilutive capital, which may reflect underlying financial constraints or limited cash flow from operations.
• ●The absence of operational, revenue, or cash position disclosures in this announcement means investors cannot assess the company's ability to meet future obligations or fund ongoing development, increasing uncertainty around long-term financial sustainability.

Bottom line

Defence Therapeutics is managing its capital structure through share-based interest payments and a multi-stage sharing agreement with Sorbie Bornholm LP, resulting in immediate dilution and ongoing settlement obligations. The company provides full transparency on the mechanics and amounts involved—$160,000 interest settled with 320,000 shares, $190,670.42 received for 606,060 shares, and 9,090,911 shares still in escrow—but does not address broader financial or operational performance. Investors should be aware that continued share issuances under these agreements will increase dilution, and the lack of financial context makes it difficult to gauge the company's underlying health. The most important takeaway is that Defence is using equity to meet financial commitments, and further dilution is likely as the Sorbie agreement progresses.

Announcement summary

(CSE:DTC) (OTCQB:DTCFF) (FSE:DTC) Defence Therapeutics Inc. announced that it has issued 320,000 common shares to holders of its convertible debentures in satisfaction of $160,000 in accrued and unpaid interest. The convertible debentures were dated September 15, 2025, have a principal amount of $2,000,000, and bear interest at a rate of 8% per annum. The 320,000 common shares issued as Interest Shares are subject to a statutory hold period of four months plus one day, in accordance with applicable securities laws. For further details regarding the Debentures, the company refers investors to its news release dated September 15, 2025, available on www.sedarplus.ca. Defence Therapeutics Inc. also provided an update on its sharing agreement dated March 6, 2026, with Sorbie Bornholm LP. The company has received the third settlement payment in the amount of $190,670.42 as of the settlement date of October 14, 2026, against 606,060 placement shares released to Sorbie Bornholm LP. As of the date of this announcement, 9,090,911 placement shares are held in escrow in connection with the sharing agreement. There are 15 settlement payments remaining under the sharing agreement. The company previously described this sharing agreement in its news releases of March 9 and February 27, 2026. The announcement covers both the interest payment in shares and the ongoing status of the sharing agreement with Sorbie Bornholm LP. The company is a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® drug-delivery platform. The announcement includes all relevant figures and dates related to the debenture interest payment and the sharing agreement settlements.

Disagree with this article?